Diagnosis and treatment of biliary tract diseases in patients with COVID-19
https://doi.org/10.25789/YMJ.2024.85.17
Abstract
The features of diagnosis and treatment of biliary tract diseases in patients with COVID-19 were studied. An increase in the number of non-calculous cholecystitis and gallbladder gangrene in severe cases of COVID-19 was revealed. The immunosuppressive effect of SARS-CoV-2, anti-inflammatory and antibacterial therapy, and multiple organ failure led to a decrease or complete absence of local symptoms and leukopenia in acute cholecystitis. In severe cases of COVID-19, the basis for diagnosing acute cholecystitis was dynamic ultrasound examination of the abdom- inal cavity, diagnostic laparoscopy and laparotomy in patients with the highest levels of leukocytosis, CRP and PCT. The greatest number of postoperative complications and deaths were observed in patients with severe COVID-19. In patients with malignant neoplasms of the biliary tract, the main symptom was “painless” jaundice. The diagnosis was confirmed by abdominal CT scan. All patients underwent minimally invasive ultrasound and endoscopic drainage operations.
About the Authors
A. A. Kaverina
Russian Far Eastern State Medical University
Russian Federation
Russian Federation
KAVERINA Anna Alexandrovna
S. A. Vavrinchuk
Russian Far Eastern State Medical University
Russian Federation
Russian Federation
VAVRINCHUK Sergey Andreevich – MD, Professor of the Department of General and Clinical Surgery
P. M. Kosenko
Russian Far Eastern State Medical University
Russian Federation
Russian Federation
KOSENKO Pavel Mikhailovich – MD, Professor of the Department of General and Clinical Surgery
N. I. Boyarintsev
Russian Far Eastern State Medical University
Russian Federation
Russian Federation
BOYARINTSEV Nikolay Ivanovich – MD, Professor of the Department of General and Clinical Surgery
G. E. Sherbakov
Russian Far Eastern State Medical University
Russian Federation
Russian Federation
SHERBAKOV Georgy Evgenievich
References
1. Vremenny`e metodicheskie rekomendacii po diagnostike, profilaktike i lecheniyu COVID-19 [Temporary methodic recommendations for diagnostics, prevention and treatment of COVID-19. Ministry of Health of the Russian Federation: [website]. — URL: https://minzdrav.gov. ru/system/attachments/attaches/000/050/122/ original/28042020_МR_COVID-19_v6.pdf (accessed on: 15.12.2023) (In Russ.).]
2. Clinical recommendations Acute cholecystitis [Klinicheskie rekomendacii Ostry`j xolecistit]. [Electronic source]. CR Rubrics: [website]. – URL: 16 https://cr.minzdrav.gov.ru/schema/324_2 (accessed on: 15.12.2023) (In Russ.).]
3. Kudryavtsev Yu.S., Beregov M.M., Berdalin A.B., Lelyuk V.G. Sravnenie osnovny`x shkal oce tyazhesti porazheniya legkix pri COVID-19 po danny`m komp`yuternoj tomografii i ocenka ix prognosticheskoj cennosti [Comparison of the main scales for assessing the severity of lung damage in COVID-19 according to computed tomography data and assessment of their prognostic value]. Vestnik rentgenologii i radiologii [Bulletin of Radiology and Radiology. 2021; 102(5): 296–303 (In Russ.).] https://doi.org/10.20862/0042-4676-2021-102-5-296-303
4. Timerbulatov V.M, Timerbulatov Sh.V, Timerbulatov M.V. Classification of surgical complications [Klassifikaciya xirurgicheskix oslozhnenij (s kommentariem redkollegii)]. Khirurgiya. Zurnal im. N.I. Pirogova [Pirogov Russian Journal of Surgery. 2018;(9):62 67 (In Russ.) https:// doi.org/10.17116/hirurgia2018090162
5. Bolek T, Samoš M, Jurica J, Stančiaková L, Péč MJ, Škorňová I, Galajda P, Staško J, Mokáň M, Kubisz P. COVID-19 and the Response to Antiplatelet Therapy. J Clin Med. 2023 Mar 4;12(5):2038. doi: 10.3390/jcm12052038. PMID: 36902825; PMCID: PMC10004309.
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation". Journal of Chronic Diseases. 40 (5): 373–383. doi:10.1016/00219681(87)90171-8. PMID 3558716.
7. Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyciński J, Lorzadeh S, Kotfis K, Ghavami S, Łos MJ. An update on drugs with therapeutic potential for SARSCoV-2 (COVID-19) treatment. Drug Resist Updat. 2021 Dec;59:100794. doi: 10.1016/j. drup.2021.100794. Epub 2021 Dec 9. PMID: 34991982; PMCID: PMC8654464.
8. Graham Teasdale, Bryan Jennett. ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS (англ.) // The Lancet. – 1974-07. – Vol. 304, iss. 7872. – P. 81–84. – doi:10.1016/S0140-6736(74)91639-0
9. Kariya A, Krutsri C, Singhatas P, Sumritpradit P, Thampongsa T, Lertsitthichai P, Phoprom N. Incidence of complicated appendicitis during the COVID-19 pandemic: A systematic review and meta-analysis. Int J Surg Open. 2022 Aug;45:100512. doi: 10.1016/j.ijso.2022.100512. Epub 2022 Jul 12. PMID: 35845315; PMCID: PMC9273516.
10. Oodit R, Biccard BM, Panieri E, Alvarez AO, Sioson MRS, Maswime S, Thomas V, Kluyts HL, Peden CJ, de Boer HD, Brindle M, Francis NK, Nelson G, Gustafsson UO, Ljungqvist O. Guidelines for Perioperative Care in Elective Abdominal and Pelvic Surgery at Primary and Secondary Hospitals in Low-Middle-Income Countries (LMIC's): Enhanced Recovery After Surgery (ERAS) Society Recommendation. World J Surg. 2022 Aug;46(8):1826-1843. doi: 10.1007/s00268-022-06587-w. Epub 2022 May 31. PMID: 35641574; PMCID: PMC9154207.
11. Piotrowicz K, Gąsowski J, Michel JP, Veronese N. Post-COVID-19 acute sarcopenia: physiopathology and management. Aging Clin Exp Res. 2021 Oct;33(10):2887-2898. doi: 10.1007/s40520-021-01942-8. Epub 2021 Jul 30. PMID: 34328636; PMCID: PMC8323089.
12. Wang Y, Perlman S. COVID-19: Inflammatory Profile. Annu Rev Med. 2022 Jan 27;73:6580. doi: 10.1146/annurev-med-042220-012417. Epub 2021 Aug 26. PMID: 34437814.
13. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782793. doi: 10.1001/jama.2020.12839. [PubMed] [CrossRef] [Google Scholar
14. Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G, Kozaka K, Endo I, Deziel DJ, Miura F, Okamoto K, Hwang TL, Huang WS, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Noguchi Y, Shikata S, Ukai T, Higuchi R, Gabata T, Mori Y, Iwashita Y, Hibi T, Jagannath P, Jonas E, Liau KH, Dervenis C, Gouma DJ, Cherqui D, Belli G, Garden OJ, Giménez ME, de Santibañes E, Suzuki K, Umezawa A, Supe AN, Pitt HA, Singh H, Chan ACW, Lau WY, Teoh AYB, Honda G, Sugioka A, Asai K, Gomi H, Itoi T, Kiriyama S, Yoshida M, Mayumi T, Matsumura N, Tokumura H, Kitano S, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54. doi: 10.1002/jhbp.515. Epub 2018 Jan 9. PMID: 29032636.
15. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023 Jan 26;14:1125246. doi: 10.3389/ fimmu.2023.1125246. PMID: 36776881; PMCID: PMC9909293.
16. Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acute-illness severity in the NHS. Report of a working party. London: RCP, 2012. Availbale at: www. rcplondon.ac.uk/file/32/ download?token=5NwjEyTq.
Review
For citations:
Kaverina A.A., Vavrinchuk S.A., Kosenko P.M., Boyarintsev N.I., Sherbakov G.E. Diagnosis and treatment of biliary tract diseases in patients with COVID-19. Yakut Medical Journal. 2024;(1):65-69. https://doi.org/10.25789/YMJ.2024.85.17
Views:
24
Email this article 